by mp3dotcombaby Oct 25, 2012 5:29 PM - "Going to take 24 months for the trial, then another 6 months minimum for NDA."
"Estimated Primary Completion Date: December 2014"
"ClinicalTrials.gov processed this record on February 21, 2013"
ClinicalTrials.gov Identifier: NCT01737814
This study is currently recruiting participants.
Verified January 2013 by Adventrx Pharmaceuticals
Sponsor: Adventrx Pharmaceuticals
First received: November 27, 2012
Last updated: January 30, 2013
Last verified: January 2013
The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.
Estimated Enrollment: 388
Study Start Date: January 2013
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
ClinicalTrials.gov processed this record on February 21, 2013
According to website, secform4, and Yahoo Finance Summary - Major Holders, Brian Culley :
Purchase 14,000 shares Average price $0.5817
Purchase 20,500 shares Average price $0.5904
Shares Ownership 34,500 (Direct)
Per 10-Q filed on 11/05/2012 - 47,715,709 shares issued and outstanding at both September 30, 2012 and December 31, 2011
34,500 / 47,715,709 = 0.000723032 i.e. 0.072303232%